SA521422304B1 - مركبات تشارك في الارتباط التعاوني واستخداماتها - Google Patents
مركبات تشارك في الارتباط التعاوني واستخداماتهاInfo
- Publication number
- SA521422304B1 SA521422304B1 SA521422304A SA521422304A SA521422304B1 SA 521422304 B1 SA521422304 B1 SA 521422304B1 SA 521422304 A SA521422304 A SA 521422304A SA 521422304 A SA521422304 A SA 521422304A SA 521422304 B1 SA521422304 B1 SA 521422304B1
- Authority
- SA
- Saudi Arabia
- Prior art keywords
- compounds
- participate
- oncogene homolog
- viral oncogene
- sarcoma viral
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/504—Pyridazines; Hydrogenated pyridazines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/04—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having less than three double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862783816P | 2018-12-21 | 2018-12-21 | |
| US201962894493P | 2019-08-30 | 2019-08-30 | |
| US201962930489P | 2019-11-04 | 2019-11-04 | |
| PCT/US2019/068100 WO2020132597A1 (en) | 2018-12-21 | 2019-12-20 | Compounds that participate in cooperative binding and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SA521422304B1 true SA521422304B1 (ar) | 2023-12-21 |
Family
ID=71099011
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SA521422304A SA521422304B1 (ar) | 2018-12-21 | 2021-06-17 | مركبات تشارك في الارتباط التعاوني واستخداماتها |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20200197391A1 (https=) |
| EP (1) | EP3897644A4 (https=) |
| JP (2) | JP7721052B2 (https=) |
| KR (1) | KR20210116479A (https=) |
| CN (1) | CN113498342A (https=) |
| AU (2) | AU2019401466B2 (https=) |
| BR (1) | BR112021012057A2 (https=) |
| CA (1) | CA3123869A1 (https=) |
| IL (2) | IL317393A (https=) |
| MX (2) | MX2021007468A (https=) |
| SA (1) | SA521422304B1 (https=) |
| SG (1) | SG11202106605VA (https=) |
| TW (1) | TW202600561A (https=) |
| WO (1) | WO2020132597A1 (https=) |
Families Citing this family (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201629069A (zh) * | 2015-01-09 | 2016-08-16 | 霍普驅動生物科技股份有限公司 | 參與協同結合之化合物及其用途 |
| KR102598895B1 (ko) | 2016-07-12 | 2023-11-07 | 레볼루션 메디슨즈, 인크. | 다른자리 입체성 shp2 억제제로서의 2,5-이치환 3-메틸 피라진 및 2,5,6-3치환 3-메틸 피라진 |
| MX2019008695A (es) | 2017-01-23 | 2019-09-11 | Revolution Medicines Inc | Compuestos biciclicos como inhibidores alostericos de shp2. |
| MX2019008696A (es) | 2017-01-23 | 2019-09-13 | Revolution Medicines Inc | Compuestos de piridina como inhibidores de shp2 alostericos. |
| MX2020003579A (es) | 2017-10-12 | 2020-07-22 | Revolution Medicines Inc | Compuestos de piridina, pirazina, y triazina como inhibidores de shp2 alostericos. |
| BR112020009757A2 (pt) | 2017-12-15 | 2020-11-03 | Revolution Medicines, Inc. | compostos policíclicos como inibidores alostéricos de shp2 |
| KR20210116479A (ko) * | 2018-12-21 | 2021-09-27 | 레볼루션 메디슨즈, 인크. | 공동 결합에 참여하는 화합물 및 그의 용도 |
| WO2021091956A1 (en) | 2019-11-04 | 2021-05-14 | Revolution Medicines, Inc. | Ras inhibitors |
| CN120699039A (zh) * | 2019-11-04 | 2025-09-26 | 锐新医药公司 | Ras抑制剂 |
| MX2022005359A (es) | 2019-11-04 | 2022-06-02 | Revolution Medicines Inc | Inhibidores de ras. |
| US20210322405A1 (en) * | 2020-04-15 | 2021-10-21 | Washington University | Compositions and methods for treating cancer |
| IL299131A (en) | 2020-06-18 | 2023-02-01 | Revolution Medicines Inc | Methods for delaying, preventing and treating acquired resistance to RAS inhibitors |
| MX2023002248A (es) | 2020-09-03 | 2023-05-16 | Revolution Medicines Inc | Uso de inhibidores de sos1 para tratar neoplasias malignas con mutaciones de shp2. |
| MX2023003060A (es) | 2020-09-15 | 2023-04-05 | Revolution Medicines Inc | Derivados indolicos como inhibidores de ras en el tratamiento del cancer. |
| AU2021401741A1 (en) * | 2020-12-17 | 2023-06-29 | Blossomhill Therapeutics, Inc. | Macrocycles and their use |
| CN116635076A (zh) * | 2020-12-17 | 2023-08-22 | 荣山医药股份有限公司 | 大环化合物及其用途 |
| IL307396A (en) * | 2021-04-02 | 2023-12-01 | Massachusetts Gen Hospital | Methods for inhibiting RAS |
| US20240217960A1 (en) * | 2021-04-09 | 2024-07-04 | Universität Basel | Triazine derivative as covalent inhibitors of pi3k |
| WO2022235866A1 (en) | 2021-05-05 | 2022-11-10 | Revolution Medicines, Inc. | Covalent ras inhibitors and uses thereof |
| CA3217393A1 (en) | 2021-05-05 | 2022-11-10 | Elena S. Koltun | Ras inhibitors |
| AU2022268962A1 (en) * | 2021-05-05 | 2023-12-14 | Revolution Medicines, Inc. | Ras inhibitors for the treatment of cancer |
| MX2023013912A (es) | 2021-05-25 | 2024-02-12 | Revolution Medicines Inc | Metodos para inhibir ras. |
| EP4346826A4 (en) * | 2021-05-27 | 2025-04-30 | Mirati Therapeutics, Inc. | COMBINATION THERAPIES |
| WO2023015559A1 (en) * | 2021-08-13 | 2023-02-16 | Nutshell Biotech (Shanghai) Co., Ltd. | Macrocycle compounds as inhibitors of ras |
| AR126854A1 (es) | 2021-08-27 | 2023-11-22 | Hoffmann La Roche | Compuestos macrocíclicos para el tratamiento de cáncer |
| AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
| TW202340214A (zh) | 2021-12-17 | 2023-10-16 | 美商健臻公司 | 做為shp2抑制劑之吡唑并吡𠯤化合物 |
| EP4227307A1 (en) | 2022-02-11 | 2023-08-16 | Genzyme Corporation | Pyrazolopyrazine compounds as shp2 inhibitors |
| CN119136806A (zh) | 2022-03-08 | 2024-12-13 | 锐新医药公司 | 用于治疗免疫难治性肺癌的方法 |
| TW202400607A (zh) * | 2022-04-25 | 2024-01-01 | 美商翰森生物有限責任公司 | 環狀化合物、製備方法及其醫藥用途 |
| CN119301132A (zh) | 2022-06-01 | 2025-01-10 | 豪夫迈·罗氏有限公司 | 用于治疗癌症的卤代吲哚大环化合物 |
| WO2023240263A1 (en) * | 2022-06-10 | 2023-12-14 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| EP4582426A4 (en) * | 2022-09-19 | 2025-12-24 | Adlai Nortye Biopharma Co Ltd | PAN-KRAS INHIBITOR COMPOUND |
| CN117720556A (zh) * | 2022-09-19 | 2024-03-19 | 杭州阿诺生物医药科技有限公司 | 一种pan-KRAS抑制剂化合物及其制备方法和用途 |
| CN119522225A (zh) | 2022-09-29 | 2025-02-25 | 广州嘉越医药科技有限公司 | 大环衍生物及其应用 |
| CN118373832B (zh) * | 2023-01-20 | 2025-01-28 | 深圳晶蛋生物医药科技有限公司 | 大环类化合物、其药物组合物及其应用 |
| CR20250329A (es) | 2023-02-14 | 2025-09-12 | Hoffmann La Roche | Compuestos tricíclicos para el tratamiento del cáncer |
| EP4687905A1 (en) | 2023-03-30 | 2026-02-11 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| CN121263418A (zh) | 2023-04-07 | 2026-01-02 | 锐新医药公司 | 大环ras抑制剂 |
| KR20260005904A (ko) | 2023-04-07 | 2026-01-12 | 레볼루션 메디슨즈, 인크. | 매크로사이클릭 ras 억제제 |
| AU2024252105A1 (en) | 2023-04-14 | 2025-10-16 | Revolution Medicines, Inc. | Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof |
| KR20250172857A (ko) | 2023-04-14 | 2025-12-09 | 레볼루션 메디슨즈, 인크. | Ras 억제제의 결정형 |
| CN116284045A (zh) * | 2023-05-18 | 2023-06-23 | 西南交通大学 | 一种手性吲哚单元取代的四氢异喹啉化合物及其合成方法 |
| EP4720072A2 (en) * | 2023-05-26 | 2026-04-08 | Revolution Medicines, Inc. | Ras inhibitors |
| CN116570599B (zh) * | 2023-07-04 | 2023-10-20 | 四川大学华西医院 | Vs6766联合ly3009120的应用及药物组合物 |
| IL326136A (en) | 2023-08-07 | 2026-03-01 | Revolution Medicines Inc | RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025090809A1 (en) * | 2023-10-25 | 2025-05-01 | Kumquat Biosciences Inc. | Macrocyclic heterocycles and uses thereof |
| CN117567483B (zh) * | 2023-11-23 | 2025-10-21 | 济南市中心医院 | 一种通过金催化的不对称环加成反应及动力学拆分合成手性氮杂八元环类化合物的方法 |
| WO2025162395A1 (zh) * | 2024-02-01 | 2025-08-07 | 山东先声生物制药有限公司 | 吲哚衍生物作为ras抑制剂及其应用 |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025214350A1 (en) * | 2024-04-08 | 2025-10-16 | Sunrise Oncology (Hong Kong) Limited | Macrocyclic compounds as ras inhibitors for the treatment of cancer |
| WO2025217307A1 (en) | 2024-04-09 | 2025-10-16 | Revolution Medicines, Inc. | Methods for predicting response to a ras(on) inhibitor and combination therapies |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026046393A1 (zh) * | 2024-09-02 | 2026-03-05 | 山东先声再明生物制药有限公司 | 吲哚类衍生物的制备及其应用 |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7601852B2 (en) * | 2006-05-11 | 2009-10-13 | Kosan Biosciences Incorporated | Macrocyclic kinase inhibitors |
| AU2011214135B2 (en) * | 2010-02-09 | 2014-07-31 | Neurovive Pharmaceutical Ab | Sanglifehrin based compounds |
| AU2012257513B2 (en) * | 2011-05-19 | 2017-05-11 | Fundación Del Sector Público Estatal Centro Nacional De Investigaciones Oncológicas Carlos III (F.S.P. CNIO) | Macrocyclic compounds as protein kinase inhibitors |
| AR091279A1 (es) * | 2012-06-08 | 2015-01-21 | Gilead Sciences Inc | Inhibidores macrociclicos de virus flaviviridae |
| KR20240093922A (ko) * | 2017-04-05 | 2024-06-24 | 레볼루션 메디슨즈, 인크. | 단백질-단백질 계면을 분석하기 위한 방법 및 시약 |
| KR20210116479A (ko) * | 2018-12-21 | 2021-09-27 | 레볼루션 메디슨즈, 인크. | 공동 결합에 참여하는 화합물 및 그의 용도 |
-
2019
- 2019-12-20 KR KR1020217022312A patent/KR20210116479A/ko active Pending
- 2019-12-20 JP JP2021535755A patent/JP7721052B2/ja active Active
- 2019-12-20 IL IL317393A patent/IL317393A/en unknown
- 2019-12-20 TW TW114110001A patent/TW202600561A/zh unknown
- 2019-12-20 CA CA3123869A patent/CA3123869A1/en active Pending
- 2019-12-20 AU AU2019401466A patent/AU2019401466B2/en active Active
- 2019-12-20 BR BR112021012057-2A patent/BR112021012057A2/pt unknown
- 2019-12-20 IL IL284210A patent/IL284210B2/en unknown
- 2019-12-20 CN CN201980092760.0A patent/CN113498342A/zh active Pending
- 2019-12-20 EP EP19901393.9A patent/EP3897644A4/en active Pending
- 2019-12-20 MX MX2021007468A patent/MX2021007468A/es unknown
- 2019-12-20 WO PCT/US2019/068100 patent/WO2020132597A1/en not_active Ceased
- 2019-12-20 US US16/723,438 patent/US20200197391A1/en not_active Abandoned
- 2019-12-20 SG SG11202106605VA patent/SG11202106605VA/en unknown
-
2021
- 2021-06-17 SA SA521422304A patent/SA521422304B1/ar unknown
- 2021-06-18 MX MX2025001810A patent/MX2025001810A/es unknown
-
2023
- 2023-03-16 US US18/184,766 patent/US20240139185A1/en not_active Abandoned
-
2024
- 2024-11-22 JP JP2024203859A patent/JP2025037925A/ja active Pending
-
2025
- 2025-07-16 AU AU2025205500A patent/AU2025205500A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019401466A1 (en) | 2021-07-01 |
| TW202600561A (zh) | 2026-01-01 |
| JP2025037925A (ja) | 2025-03-18 |
| MX2021007468A (es) | 2021-08-05 |
| AU2019401466B2 (en) | 2025-04-24 |
| US20200197391A1 (en) | 2020-06-25 |
| US20240139185A1 (en) | 2024-05-02 |
| KR20210116479A (ko) | 2021-09-27 |
| IL284210B2 (en) | 2025-05-01 |
| WO2020132597A1 (en) | 2020-06-25 |
| AU2025205500A1 (en) | 2025-07-31 |
| IL284210A (en) | 2021-08-31 |
| EP3897644A4 (en) | 2022-09-07 |
| CA3123869A1 (en) | 2020-06-25 |
| BR112021012057A2 (pt) | 2021-10-19 |
| JP2022520154A (ja) | 2022-03-29 |
| SG11202106605VA (en) | 2021-07-29 |
| TW202039509A (zh) | 2020-11-01 |
| CN113498342A (zh) | 2021-10-12 |
| IL317393A (en) | 2025-02-01 |
| JP7721052B2 (ja) | 2025-08-12 |
| MX2025001810A (es) | 2025-03-07 |
| WO2020132597A8 (en) | 2020-07-16 |
| IL284210B1 (en) | 2025-01-01 |
| EP3897644A1 (en) | 2021-10-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SA521422304B1 (ar) | مركبات تشارك في الارتباط التعاوني واستخداماتها | |
| ZA202204754B (en) | Ras inhibitors | |
| PH12022550988A1 (en) | Ras inhibitors | |
| PH12022550973A1 (en) | Ras inhibitors | |
| MX2023013085A (es) | Inhibidores de ras. | |
| MX2025008493A (es) | Agentes de union a fibroblastos y uso de estos | |
| MX2024015215A (es) | Inhibidores macrociclicos de ras | |
| MX2025009223A (es) | Agentes de union a clec9a y su uso | |
| PH12020551043A1 (en) | Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues | |
| MX2020006128A (es) | Inhibidores de la proteina de activacion de fibroblastos. | |
| MX388533B (es) | Compuestos de benzoxacepina oxazolidinona y métodos de uso. | |
| EA201890146A1 (ru) | СПОСОБЫ ЛЕЧЕНИЯ СОЛИДНЫХ ОПУХОЛЕЙ С ИСПОЛЬЗОВАНИЕМ КОМБИНИРОВАННОЙ ТЕРАПИИ ИНГИБИТОРОМ mTOR В ВИДЕ НАНОЧАСТИЦ | |
| BR112017007708A2 (pt) | composto macrocíclicos, uso de um composto macrocíclicos, método para tratamento, unidade de dose, composição farmacêutica e método para tratar câncer em um paciente | |
| WO2018042438A3 (en) | Human blood-derived products having decreased fibrinolytic activity and uses thereof in hemostatic disorders | |
| MX2021001807A (es) | Combinacion de un inhibidor de histona desacetilasa y un inhibidor de proteina cinasa y uso farmaceutico de la misma. | |
| GEP20217327B (en) | Spirocycle compounds and methods of making and using same | |
| EA201891609A1 (ru) | Производные 3-((гетеро-)арил)алкил-8-амино-2-оксо-1,3-диазаспиро[4.5]декана | |
| MX2021011723A (es) | Ligandos de pseudocinasa tyk2. | |
| PH12021550872A1 (en) | Therapeutic compounds | |
| MX2021001612A (es) | Compuestos utiles en terapia del vih. | |
| MX2018008640A (es) | Derivados de 3-(carboxietil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]- decano. | |
| EA202190281A1 (ru) | Производные 3-((гетеро-)арил)-8-амино-2-оксо-1,3-диаза-спиро[4,5]декана | |
| EA201891473A1 (ru) | Комбинированная терапия | |
| EA202091112A1 (ru) | Сокристаллы, фармацевтические композиции на их основе и способы лечения, предусматривающие их применение | |
| ZA201805358B (en) | 3-(carboxymethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives |